281 related articles for article (PubMed ID: 25655295)
1. Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells.
Zhong J; Huang HL; Li J; Qian FC; Li LQ; Niu PP; Dai LC
Hepatobiliary Pancreat Dis Int; 2015 Feb; 14(1):82-9. PubMed ID: 25655295
[TBL] [Abstract][Full Text] [Related]
2. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.
Younis MA; Khalil IA; Abd Elwakil MM; Harashima H
Mol Pharm; 2019 Sep; 16(9):4031-4044. PubMed ID: 31403802
[TBL] [Abstract][Full Text] [Related]
3. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
4. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
[TBL] [Abstract][Full Text] [Related]
5. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
6. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.
Bie CQ; Liu XY; Cao MR; Huang QY; Tang HJ; Wang M; Cao GL; Yi TZ; Wu SL; Xu WJ; Tang SH
Oncotarget; 2016 Nov; 7(48):79305-79318. PubMed ID: 27813495
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells.
Dai LC; Wang X; Yao X; Lu YL; Ping JL; He JF
Acta Pharmacol Sin; 2006 Dec; 27(12):1630-6. PubMed ID: 17112419
[TBL] [Abstract][Full Text] [Related]
8. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
9. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.
Wang K; Kievit FM; Sham JG; Jeon M; Stephen ZR; Bakthavatsalam A; Park JO; Zhang M
Small; 2016 Jan; 12(4):477-87. PubMed ID: 26641029
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA.
Shi Y; Wang SY; Yao M; Sai WL; Wu W; Yang JL; Cai Y; Zheng WJ; Yao DF
World J Gastroenterol; 2015 Dec; 21(45):12814-21. PubMed ID: 26668505
[TBL] [Abstract][Full Text] [Related]
11. [Interferon-induced transmembrane protein 3 knock-down inhibits proliferation and invasion of hepatocellular carcinoma HepG2 cells in vitro].
Wu RS; Wu LQ; Li KH; Li EL; Feng Q; Zhang JL
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Feb; 36(2):244-9. PubMed ID: 26922024
[TBL] [Abstract][Full Text] [Related]
12. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo.
Younis MA; Khalil IA; Elewa YHA; Kon Y; Harashima H
J Control Release; 2021 Mar; 331():335-349. PubMed ID: 33484779
[TBL] [Abstract][Full Text] [Related]
13. Midkine accumulated in nucleolus of HepG2 cells involved in rRNA transcription.
Dai LC; Shao JZ; Min LS; Xiao YT; Xiang LX; Ma ZH
World J Gastroenterol; 2008 Oct; 14(40):6249-53. PubMed ID: 18985819
[TBL] [Abstract][Full Text] [Related]
14. Diethylaminoethyl- chitosan as an efficient carrier for siRNA delivery: Improving the condensation process and the nanoparticles properties.
de Souza RHFV; Picola IPD; Shi Q; Petrônio MS; Benderdour M; Fernandes JC; Lima AMF; Martins GO; Martinez Junior AM; de Oliveira Tiera VA; Tiera MJ
Int J Biol Macromol; 2018 Nov; 119():186-197. PubMed ID: 30031084
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.
Jia XQ; Cheng HQ; Li H; Zhu Y; Li YH; Feng ZQ; Zhang JP
Chin Med J (Engl); 2011 Nov; 124(22):3794-9. PubMed ID: 22340243
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effect of blocking expression of human augmenter of liver regeneration (hALR) on proliferation of hepatocellular carcinoma cell line HepG2].
Tang L; Sun H; Zhang L; Guo H; Zhang L; Liu Q
Ai Zheng; 2006 Jun; 25(6):671-6. PubMed ID: 16764759
[TBL] [Abstract][Full Text] [Related]
18. Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes.
Jean M; Alameh M; De Jesus D; Thibault M; Lavertu M; Darras V; Nelea M; Buschmann MD; Merzouki A
Eur J Pharm Sci; 2012 Jan; 45(1-2):138-49. PubMed ID: 22085632
[TBL] [Abstract][Full Text] [Related]
19. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
20. Novel biotinylated chitosan-graft-polyethyleneimine copolymer as a targeted non-viral vector for anti-EGF receptor siRNA delivery in cancer cells.
Darvishi MH; Nomani A; Amini M; Shokrgozar MA; Dinarvand R
Int J Pharm; 2013 Nov; 456(2):408-16. PubMed ID: 24012865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
